Overexpression of MMP-1 is associated with several pathological conditions, including the irreversible degradation of cartilage, tendon, and bone in arthritis and the degradation of collagens I and III in tumor invasion and metastasis. Patients with tumors that express MMP-1 have an overall poorer prognosis than patients with tumors that do not express this protein.
Dartmouth researchers have now found that the expression of a MMP-1-specific short interfering RNA molecule in a breast cancer cell can significantly reduce the expression of MMP-1 mRNA and protein in the cancer cell, block the destruction of collagen matrix, and significantly decrease the size of tumors formed by these cells in nude mice. Accordingly, compositions which target MMP-1 nucleic acid sequences are expected to be useful in preventing, treating and managing cancer by suppressing invasion or metastasis of tumor cells.
This technology is claimed in the issued United States Patent Application No. 7,511,025 and the published United States Patent Application No. 12/352,214. We are seeking an industrial partner interested in its commercialization. (Ref: J271)
Last Updated: 7/24/12